RxDoctor Payments Data

Sandra Tyler, PA

Medical · Suwanee, GANPI 1588963490

Payments from drug & device makers

$3,388in general payments, 2019–2025

Across 144 payments — averaging $23.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$710
  • Lilly USA, LLC$293
  • Bayer$231
  • Xeris Pharmaceuticals, Inc.$204
  • GSK$191
  • Amgen$190
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$3,388100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,388 in reported general payments places this provider in the 75th percentile of 950 medical providers in Georgia.

See all medical providers in Georgia

Medicare billing

Part B allowed, 2024
$21,724
Medicare patients
51
Services billed
1,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$83,291
MounjaroTirzepatide24$24,818
Tresiba Flextouch U-100Insulin Degludec18$22,652
FarxigaDapagliflozin Propanediol21$18,216
TrulicityDulaglutide14$14,730
Novolog FlexpenInsulin Aspart33$14,299
TradjentaLinagliptin16$9,373
NovologInsulin Aspart11$1,899
Nano 2nd Gen Pen NeedlePen Needle, Diabetic11$1,709
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,657
Levothyroxine Sodium42$369
Metformin Hcl ErMetformin Hcl23$220
Gabapentin18$214
Atorvastatin Calcium27$148
Pioglitazone Hcl15$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$710$85,19075 claims
Lilly USA, LLCMounjaro, Trulicity$293$39,54838 claims
AstraZenecaFarxiga$77$18,21621 claims
Boehringer IngelheimTradjenta$32$9,37316 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$36942 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 950 medical providers in Georgia.

Other medical in Suwanee

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →